Combinative Strategy Using Tamoxifen and Other Chemotherapeutic Drugs for Cholangiocarcinoma Chemotherapy
Zhihua Liu,Yanlei Ma,Huanlong Qin
DOI: https://doi.org/10.1002/hep.23900
IF: 17.298
2010-01-01
Hepatology
Abstract:We read in HEPATOLOGY a very interesting and valuable article1 suggesting that the simultaneous targeting of epidermal growth factor receptor (ErbB1) and human epidermal growth factor receptor 2 (ErbB2) could potentially be a selective strategy for cholangiocarcinoma therapy. Reading this article and considering our own study on the treatment of cholangiocarcinoma with a combinative strategy involving tamoxifen and other chemotherapeutic drugs, we see indications that the use of tamoxifen for cholangiocarcinoma prevention and treatment will become more popular. Tamoxifen is a classic drug for estrogen receptor–positive primary breast cancer that is positive for ErbB1 and/or ErbB2,2 and the same mechanism could be indicated for the treatment of cholangiocarcinoma. We have also performed some experiments with this strategy (as mentioned later), and now we think that the expression levels of ErbB1, ErbB2, or both could be markers for the effects of tamoxifen. To find new ways of using chemotherapeutics for human cholangiocarcinoma, we have been paying attention to the growth-inhibition effects of tamoxifen in combination chemotherapeutics. Some of our pilot studies have shown that tamoxifen can lead to increased cell damage by competing with other chemotherapeutic molecules for binding sites on P-glycoprotein and by limiting the extracellular transport of drugs from the human cholangiocarcinoma cell line QBC939.3, 4 Because cholangiocarcinoma cells gradually develop resistance to conventional chemotherapeutic drugs, we have selected tamoxifen as a sensitizer that competes with chemotherapeutic drugs as the P-glycoprotein substrate for the P-glycoprotein binding site and enhances the drug concentration and effects of chemotherapy.3 To further our study, we have established a human, multidrug-resistant cholangiocarcinoma cell line (QBC939/ADM).4 We are now investigating the specific signal transduction pathway by which tamoxifen decreases P-glycoprotein expression levels, and we are determining whether other mechanisms are involved. Furthermore, tamoxifen has been used primarily to treat patients with nonbreast cancers, including hepatocellular, pancreatic, renal cell, ovarian, and melanoma carcinomas.3 Above all, we believe that although the use of tamoxifen for the prevention of breast cancer is exceptionally low, the use of tamoxifen for cancer prevention and treatment will become more popular and extensive with the decision-making process. Zhihua Liu Ph.D.*, Yanlei Ma Ph.D.*, Huanlong Qin M.D.*, * Department of Surgery, Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.